The board of directors unanimously approved the transaction, expected to close by the end of 2025, pending regulatory and shareholder approvals. ZimVie retains the right to solicit superior offers through August 29.

CEO Vafa Jamali highlighted the deal as a milestone for ZimVie, emphasizing Archimed’s potential to support the company’s global expansion in dental technology. If completed, ZimVie will become a private company and be delisted from Nasdaq.

The deal follows ZimVie’s 2023 sale of its spine unit to H.I.G. Capital for $375 million. Archimed Managing Partner André-Michel Ballester called ZimVie’s fundamentals “strong” and its growth “compelling.”

Follow MEDWIRE.AI for the latest on MedTech mergers and acquisitions.

The deal combines Waters’ strength in liquid chromatography and mass spectrometry with BD’s capabilities in flow cytometry and diagnostics, doubling Waters’ total addressable market to about $40 billion. BD first revealed plans to divest the unit earlier this year, with speculation around multiple buyers.

Leaders expect the combination to deliver $200 million in cost synergies by year three, growing to $345 million in annualized EBITDA synergies by 2030. BD will receive a $4 billion cash distribution, using at least half for share buybacks and the rest for debt repayment.

Waters CEO Udit Batra will lead the combined company, which aims to accelerate growth in bioseparations, bioanalytical characterization and multiplex diagnostics. The transaction is expected to close by Q1 2026, pending approvals.

Follow MEDWIRE.AI for updates on life science M&A and diagnostics market moves.

The deal follows Acutus’s strategic realignment and exit from the electrophysiology mapping and ablation business, after previously selling its left-heart access portfolio to Medtronic.

AcQMap employs voltage-to-charge-density mapping for enhanced spatial resolution. EnChannel’s integrated platform combines magnetic-impedance navigation, intracardiac echocardiography, 5D action-potential mapping, and pulsed-field ablation to advance atrial fibrillation (AF) treatment.

“This acquisition accelerates our mission to visualize and treat AF with unprecedented precision,” said Jun Feng, CEO of EnChannel Medical.

Follow MEDWIRE.AI for AFib and electrophysiology technology updates.

While the Marlborough, MA-based company declined the bid, sources say the deal could resurface. Hologic faces potential headwinds, including manufacturing tariffs in China and Costa Rica and reduced demand—factors that recently led to lowered profit projections.

The news caused Hologic’s stock to surge nearly 20%, with shares up another 2.3% to $63.65.

Private equity remains active in medtech, with past moves involving Medtronic, J&J, Baxter, and others. Hologic, generating over $4B annually, ranks as the 30th largest medtech company globally.

Follow MEDWIRE.AI for the latest in medtech M&A trends.

This milestone allows eligible patients access starting Feb. 1, ahead of a broader rollout on July 1, 2025. The system uses focused ultrasound to mechanically destroy tumors without heat, toxicity, or surgery—an alternative for patients intolerant to standard treatments.

The move follows 12-month safety and efficacy data and comes amid acquisition rumors valuing HistoSonics at $2.5B.

Follow MEDWIRE.AI for MedTech reimbursement and M&A updates.

Key Takeaways:

• Streamlined Diagnosis: VirtuOx’s at-home diagnostic services provide patients with faster, flexible, and affordable testing, especially for conditions like sleep-disordered breathing and obstructive sleep apnea (OSA).
• Digital-First Approach: The acquisition aligns with ResMed’s goal to enhance its digital health ecosystem, making the diagnostic and treatment process more coordinated and patient-friendly.
• Improved Access to Care: ResMed aims to reduce barriers to diagnosis, accelerate time to treatment, and improve care coordination between healthcare providers, home medical equipment providers, and patients.

With the addition of VirtuOx, ResMed strengthens its position in the digital healthcare space and continues to focus on delivering life-changing therapies for patients with sleep apnea and related conditions.

Follow MEDWIRE.AI for more updates on the latest healthcare acquisitions and innovations.

Key Highlights:

• Acquisition Terms: Each NeuroMetrix (NURO) share was exchanged for $4.49 per share and a contingent value right (CVR) tied to future sales milestones of Quell and DPNCheck, a diagnostic tool for peripheral neuropathy.
• Quell: This wearable, app-enabled platform helps manage fibromyalgia and lower-extremity chronic pain, contributing to ElectroCore’s expanding addressable market.
• Strategic Positioning: The acquisition positions ElectroCore to accelerate Quell’s adoption, particularly within veteran healthcare systems, while diversifying its offerings in non-pharmaceutical nerve stimulation.

With this acquisition, ElectroCore aims to leverage its established distribution channels to drive the growth of Quell and solidify its leadership in bioelectronic technology for chronic pain management.

Follow MEDWIRE.AI for the latest updates on innovations in pain management and bioelectronics.

The deal includes Ypsomed Diabetes Care’s subsidiaries and patch pump development activities, with the transaction expected to close in the second half of 2025. Ypsomed will shift its strategic focus toward subcutaneous self-injection markets following the sale.

TecMed plans to integrate Ypsomed’s mylife Loop system—including the mylife YpsoPump and the CamAPS FX automated insulin delivery solution—into its existing patch pump development program. According to Ypsomed, TecMed’s “clear vision in diabetes care” ensures stability and continuity for patients, employees, and partners throughout the transition.

This move marks a significant consolidation in diabetes management technologies, aligning two advanced insulin delivery portfolios under one organization.

Follow MEDWIRE.AI for more medical device industry updates.

The acquisition merges RadNet’s imaging and digital health services with iCad’s AI-driven breast health technology, including the ProFound Breast Health Suite. The combined entity aims to accelerate global innovation in AI-powered breast cancer screening and diagnosis.

RadNet CEO Dr. Howard Berger said the integration will enhance early detection and diagnostic accuracy worldwide. iCad CEO Dana Brown added the partnership will fast-track access to next-gen tools for radiologists, supporting improved care delivery.

The deal, pending shareholder approval, is expected to close in Q2 or Q3 2025.

Follow MEDWIRE.AI for imaging AI and diagnostics updates.

Boston Scientific has successfully finalized its acquisition of Bolt Medical, a move that expands its capabilities in the treatment of coronary and peripheral artery disease. This acquisition follows the FDA’s recent 510(k) clearance of the Bolt IVL system, which was granted on March 25, 2025, just two months after its submission.

Strengthening the Cardiovascular Portfolio

• Strategic Investment: Boston Scientific initially helped develop the concept for Bolt’s IVL technology, which uses acoustic pressure waves to treat calcified lesions in coronary and peripheral arteries.
• Acquisition Details: The acquisition is valued at $600 million upfront, with up to an additional $300 million tied to regulatory milestones.

The Competitive IVL Landscape

Boston Scientific enters a competitive IVL space, joining Shockwave Medical, Abbott, and other rising players like FastWave Medical, Vantis Vascular, and Amplitude Vascular. The growing interest in IVL highlights its potential to transform treatment for calcified arterial disease.

Bolt Medical’s Innovative Technology

• Laser-based IVL: Bolt’s technology uses a balloon catheter to create acoustic pressure waves that fracture calcium in arteries.
• Visible Energy Delivery: Its directional emitters ensure consistent and accurate energy application during treatment.

With this acquisition, Boston Scientific is poised to expand its cardiovascular offerings, positioning itself as a key player in the growing IVL market.

Follow MEDWIRE.AI for more updates on MedTech acquisitions and innovations.